[go: up one dir, main page]

EA201591567A1 - Новые производные пиридина - Google Patents

Новые производные пиридина

Info

Publication number
EA201591567A1
EA201591567A1 EA201591567A EA201591567A EA201591567A1 EA 201591567 A1 EA201591567 A1 EA 201591567A1 EA 201591567 A EA201591567 A EA 201591567A EA 201591567 A EA201591567 A EA 201591567A EA 201591567 A1 EA201591567 A1 EA 201591567A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridine derivatives
new pyridine
new
compound
formula
Prior art date
Application number
EA201591567A
Other languages
English (en)
Other versions
EA027569B1 (ru
Inventor
Оливье Гавелль
Уве Гретер
Ацуси Кимбара
Маттиас Неттекофен
Штефан Рёфер
Марк Роджерс-Эванс
Дидье Ромбах
Танья Шульц-Гаш
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201591567A1 publication Critical patent/EA201591567A1/ru
Publication of EA027569B1 publication Critical patent/EA027569B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)

Abstract

Настоящее изобретение относится к соединению формулы (I)в котором А и R-Rопределены в описании и в формуле изобретения. Соединение формулы (I) можно применять в качестве лекарственного средства.
EA201591567A 2013-03-26 2014-03-24 Производные пиридина EA027569B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26
PCT/EP2014/055797 WO2014154612A1 (en) 2013-03-26 2014-03-24 Novel pyridine derivatives

Publications (2)

Publication Number Publication Date
EA201591567A1 true EA201591567A1 (ru) 2016-01-29
EA027569B1 EA027569B1 (ru) 2017-08-31

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591567A EA027569B1 (ru) 2013-03-26 2014-03-24 Производные пиридина

Country Status (33)

Country Link
US (2) US10308659B2 (ru)
EP (1) EP2978755B1 (ru)
JP (1) JP6500010B2 (ru)
KR (1) KR20150135458A (ru)
CN (1) CN105121436B (ru)
AR (1) AR095721A1 (ru)
AU (1) AU2014243190B2 (ru)
BR (1) BR112015024272A2 (ru)
CA (1) CA2899168A1 (ru)
CL (1) CL2015002835A1 (ru)
CR (1) CR20150440A (ru)
DK (1) DK2978755T3 (ru)
EA (1) EA027569B1 (ru)
ES (1) ES2661737T3 (ru)
HR (1) HRP20180371T1 (ru)
HU (1) HUE036934T2 (ru)
IL (1) IL240496B (ru)
LT (1) LT2978755T (ru)
MA (1) MA38404B1 (ru)
MX (1) MX365921B (ru)
MY (1) MY174000A (ru)
NO (1) NO2978755T3 (ru)
PE (1) PE20151559A1 (ru)
PH (1) PH12015501933B1 (ru)
PL (1) PL2978755T3 (ru)
PT (1) PT2978755T (ru)
RS (1) RS56927B1 (ru)
SG (1) SG11201507994QA (ru)
SI (1) SI2978755T1 (ru)
TW (1) TWI628174B (ru)
UA (1) UA116239C2 (ru)
WO (1) WO2014154612A1 (ru)
ZA (1) ZA201505251B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015190316A1 (ja) * 2014-06-09 2017-04-20 住友化学株式会社 ピリジン化合物の製造方法
MX376414B (es) 2015-12-09 2025-03-07 Hoffmann La Roche Derivados de fenilo como agonistas del receptor de canabinoides 2.
TWI737763B (zh) * 2016-07-07 2021-09-01 美商陶氏農業科學公司 製備4-烷氧基-3-(醯基或烷基)氧基吡啶醯胺之方法
TW202417417A (zh) * 2017-04-06 2024-05-01 美商富曼西公司 殺真菌之噁二唑
CN110753690B (zh) * 2017-06-20 2023-12-05 豪夫迈·罗氏有限公司 吡啶衍生物
WO2019003956A1 (ja) * 2017-06-27 2019-01-03 住友化学株式会社 オキサジアゾール化合物及びその用途
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
EP3814337B1 (en) 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
JP7478672B2 (ja) 2018-06-27 2024-05-07 エフ． ホフマン－ラ ロシュ アーゲー カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
EP3814329B1 (en) 2018-06-27 2024-01-17 F. Hoffmann-La Roche AG Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
WO2023069721A2 (en) * 2021-10-22 2023-04-27 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28
CN115073366B (zh) * 2022-06-08 2024-08-09 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法
WO2025104141A1 (en) * 2023-11-16 2025-05-22 F. Hoffmann-La Roche Ag Novel reversible fluorescent probes for cb2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492784A4 (en) * 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
NZ596024A (en) 2006-08-07 2013-07-26 Ironwood Pharmaceuticals Inc Indole compounds
US20100227845A1 (en) * 2007-10-18 2010-09-09 Zhicai Wu Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CN104395290A (zh) 2012-07-04 2015-03-04 霍夫曼-拉罗奇有限公司 作为大麻素受体2激动剂的新金刚烷基衍生物
WO2014086705A1 (en) 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Novel pyridine derivatives
PE20151060A1 (es) 2012-12-07 2015-07-25 Hoffmann La Roche Nuevos derivados de pirazina como agonistas del receptor cb2
PE20151089A1 (es) 2012-12-07 2015-08-06 Hoffmann La Roche Piridin-2-amidas utiles como agonistas de cb2
BR112015013124A2 (pt) 2012-12-07 2017-07-11 Hoffmann La Roche novos derivados de piridina
RS56148B1 (sr) 2013-03-07 2017-11-30 Hoffmann La Roche Novi derivati pirazola
CN106458984A (zh) 2014-04-04 2017-02-22 豪夫迈·罗氏有限公司 作为大麻素受体激动剂的5，6‑双取代的吡啶‑2‑甲酰胺
PE20161370A1 (es) 2014-04-04 2016-12-17 Hoffmann La Roche Nuevos derivados de piridina utiles como antagonistas de cb2

Also Published As

Publication number Publication date
RS56927B1 (sr) 2018-05-31
IL240496A0 (en) 2015-09-24
EP2978755B1 (en) 2018-01-03
PT2978755T (pt) 2018-02-26
CA2899168A1 (en) 2014-10-02
PH12015501933B1 (en) 2018-12-14
AR095721A1 (es) 2015-11-04
IL240496B (en) 2019-03-31
US10308659B2 (en) 2019-06-04
TWI628174B (zh) 2018-07-01
UA116239C2 (uk) 2018-02-26
KR20150135458A (ko) 2015-12-02
BR112015024272A2 (pt) 2017-07-18
JP6500010B2 (ja) 2019-04-10
MA38404B1 (fr) 2017-09-29
AU2014243190B2 (en) 2018-07-19
MX2015013629A (es) 2016-02-18
PL2978755T3 (pl) 2018-05-30
AU2014243190A1 (en) 2015-07-30
WO2014154612A1 (en) 2014-10-02
HUE036934T2 (hu) 2018-08-28
CN105121436A (zh) 2015-12-02
US20160016968A1 (en) 2016-01-21
PE20151559A1 (es) 2015-11-05
HRP20180371T1 (hr) 2018-04-06
MA38404A1 (fr) 2017-01-31
TW201518287A (zh) 2015-05-16
ZA201505251B (en) 2016-07-27
CR20150440A (es) 2015-10-08
EP2978755A1 (en) 2016-02-03
HK1211938A1 (en) 2016-06-03
US20190248803A1 (en) 2019-08-15
DK2978755T3 (en) 2018-03-05
JP2016516737A (ja) 2016-06-09
EA027569B1 (ru) 2017-08-31
ES2661737T3 (es) 2018-04-03
MX365921B (es) 2019-06-20
NO2978755T3 (ru) 2018-06-02
SG11201507994QA (en) 2015-10-29
MY174000A (en) 2020-03-03
CN105121436B (zh) 2018-07-27
SI2978755T1 (en) 2018-03-30
CL2015002835A1 (es) 2016-05-20
PH12015501933A1 (en) 2016-01-11
LT2978755T (lt) 2018-03-12

Similar Documents

Publication Publication Date Title
EA201591567A1 (ru) Новые производные пиридина
EA201591064A1 (ru) Новые производные пиридина
EA201591527A1 (ru) Новые производные пиридина
EA201591624A1 (ru) Новые производные пиразола
EA201690478A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201400753A1 (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
UA116920C2 (uk) Інгібітори fgfr4
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591976A1 (ru) Производные пурина в качестве агонистов каннабиноидного рецептора cb2
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
CR20150061A (es) Compuesto de pirazolopirimidinas
CR20150204A (es) Nuevos derivados de piridina
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
EA201590688A1 (ru) Производные n-проп-2-инилкарбоксамида и их применение в качестве антагонистов trpa1
EA201500931A1 (ru) Производные пиридин-4-ила
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
EA201690561A1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
UY34807A (es) Derivados monocíclicos de heteroarilcicloalquil- diamina
UY34986A (es) Derivados de diazepinona

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU